Immunotherapy after surgery for liver cancer
Part of Cancer, Immune system & allergy clinical trials.
This trial tests whether giving an immunotherapy drug after surgery can help prevent liver cancer from coming back. The drug works by helping your immune system fight any remaining cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had surgery to completely remove your liver tumor.
- Your tumor was confirmed as hepatocellular carcinoma (the most common type of liver cancer).
- Your liver function is good enough (Child-Pugh grade A or B).
- You have not had other cancer treatments for this liver tumor before.
- You do not have cancer that has spread outside the liver.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a blood test can predict if liver cancer comes back after surgery or ablation, and whether an immunotherapy drug (PD-1 inhibitor) can help prevent recurrence. It may help guide treatment to keep the cancer from returning.
This trial compares two treatments after liver cancer surgery to see which better prevents the cancer from coming back. You may be eligible if your surgery had a narrow margin and you have certain risk factors, like a tumor over 5 cm or high AFP levels.
This trial tests whether giving immunotherapy after surgery to remove liver cancer can help lower the risk of the cancer coming back. It may be an option for people who have certain risk factors for recurrence.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can lower the chance of liver cancer coming back in people who have high-risk features. It may help patients with early-stage liver cancer that can be removed surgically.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab (a drug that cuts off blood supply to the tumor) given after surgery or ablation for liver cancer. The goal is to lower the chance of cancer coming back. The treatment is given as an infusion and may help patients with certain high-risk features.
This trial tests a combination of treatments before and after surgery for liver cancer that can be removed. The goal is to see if adding targeted therapy and immunotherapy can reduce the risk of cancer coming back.
Hear when a new Adjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.